Patents by Inventor Deog J. Kim

Deog J. Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9782410
    Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: October 10, 2017
    Assignee: REXAHN PHARMACEUTICALS, INC.
    Inventors: Young B. Lee, Deog J. Kim, Reza Mazhari, Godefridus J. Peters, Dzjemma Sarkisjan
  • Patent number: 9744167
    Abstract: The present invention relates to storage stable nanoparticulate compositions of piperazine compounds. The pharmaceutical compositions comprising the nanoparticulate compositions that are useful for the treatment and prevention of proliferative diseases including cancer are also described.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: August 29, 2017
    Assignee: Rexahn Pharmaceuticals, Inc.
    Inventors: Young B. Lee, Chang-Ho Ahn, Deog J. Kim
  • Patent number: 9434610
    Abstract: Disclosed are water-soluble compositions of gemcitabine and docetaxel formed by conjugating the gemcitabine or docetaxel to a water-soluble polymer such as N-2-hydroxypropyl methacrylamide (HPMA). Also disclosed are methods of using the compositions of the invention for the treatment of cancer.
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: September 6, 2016
    Assignees: REXAHN PHARMACEUTICALS, INC., University of Maryland, Baltimore
    Inventors: Young B. Lee, Deog J. Kim, Chang H. Ahn, Anjan Nan, Hamidreza Ghandehari, Abhijit Ray
  • Patent number: 9150520
    Abstract: Processes for the preparation of 4-amino-1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one (13, RX-3117) and its intermediates are described.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: October 6, 2015
    Assignee: Rexahn Pharmaceuticals, Inc.
    Inventors: Haifeng Yin, Deog J. Kim, Eliezer Falb, Leigh A. Pearcey, Jonathan Cummins, Petra Dieterich, Jean-Francois Carniaux, Yi Wang, Vikram Chandrakant Purohit
  • Publication number: 20150071872
    Abstract: The present invention relates to compositions for the treatment of cancerous tissues in warm-blooded animals containing one or two anticancer agents attached to polymeric carriers having monomer units derived from one or more of N-(2-carboxypropyl)methacrylamide (2-CPMA), N-(3-carboxypropyl)methacrylamide (3-CPMA), N-(2-aminopropyl)methacrylamide (2-APMA) and/or N-(3-aminopropyl)methacrylamide (3-APMA) are also included. Anticancer agents in compositions can be attached to said polymeric carrier by side-chains which can be susceptible to hydrolysis by lysosomal enzymes intracellularly. Compositions can also include a targeting ligand attached to the polymeric carrier, optionally through a second linker.
    Type: Application
    Filed: September 9, 2014
    Publication date: March 12, 2015
    Inventors: Young Bok Lee, Deog J. Kim, Chang H. Ahn
  • Patent number: 8846110
    Abstract: The present invention relates to compositions for the treatment of cancerous tissues in warm-blooded animals containing one or two anticancer agents attached to polymeric carriers having monomer units derived from one or more of N-(2-carboxypropyl)methacrylamide (2-CPMA), N-(3-carboxypropyl)methacrylamide (3-CPMA), N-(2-aminopropyl)methacrylamide (2-APMA) and/or N-(3-aminopropyl)methacrylamide (3-APMA) are also included. Anticancer agents in compositions can be attached to said polymeric carrier by side-chains which can be susceptible to hydrolysis by lysosomal enzymes intracellularly. Compositions can also include a targeting ligand attached to the polymeric carrier, optionally through a second linker.
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: September 30, 2014
    Assignee: Rexahn Pharmaceuticals, Inc.
    Inventors: Young B. Lee, Deog J. Kim, Chang H. Ahn
  • Publication number: 20110086111
    Abstract: The present invention relates to compositions for the treatment of cancerous tissues in warm-blooded animals containing one or two anticancer agents attached to polymeric carriers having monomer units derived from one or more of N-(2-carboxypropyl)methacrylamide (2-CPMA), N-(3-carboxypropyl)methacrylamide (3-CPMA), N-(2-aminopropyl)methacrylamide (2-APMA) and/or N-(3-aminopropyl)methacrylamide (3-APMA) are also included. Anticancer agents in compositions can be attached to said polymeric carrier by side-chains which can be susceptible to hydrolysis by lysosomal enzymes intracellularly. Compositions can also include a targeting ligand attached to the polymeric carrier, optionally through a second linker.
    Type: Application
    Filed: October 13, 2010
    Publication date: April 14, 2011
    Applicant: Rexahn Pharmaceuticals, Inc.
    Inventors: Young B. Lee, Deog J. Kim, Chang H. Ahn
  • Publication number: 20100255099
    Abstract: The present invention generally relates to use of a stable solid pharmaceutical compositions that includes a clavulanate as the pharmaceutically active ingredients in an immediate-release or an extended-release solid dosage form. The composition can be used in a method of treating a neurodegenerative disease, providing neuroprotection, or preventing neuronal cell loss or death. Exemplary neurodegenerative diseases include Parkinson's disease, Alzheimer's disease and multiple sclerosis.
    Type: Application
    Filed: April 29, 2010
    Publication date: October 7, 2010
    Applicant: REXAHN PHARMACEUTICALS, INC.
    Inventors: Deog J. Kim, Young B. Lee, Chang H. Ahn, Edward C. Scholtz, Youngbuhm Huh
  • Publication number: 20100099644
    Abstract: Disclosed are water-soluble compositions of gemcitabine and docetaxel formed by conjugating the gemcitabine or docetaxel to a water-soluble polymer such as N-2-hydroxypropyl methacrylamide (HPMA). Also disclosed are methods of using the compositions of the invention for the treatment of cancer.
    Type: Application
    Filed: October 7, 2009
    Publication date: April 22, 2010
    Inventors: Young B. Lee, Deog J. Kim, Chang H. Ahn, Anjan Nan, Hamidreza Ghandehari, Abhijit Ray
  • Publication number: 20090270358
    Abstract: The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as potassium clavulanate or Clavitesse™, preferably in an immediate-release solid dosage form or an extended-release solid dosage form. Also provided are methods for making and using such immediate-release and stabilized compositions or extended-release and stabilized compositions.
    Type: Application
    Filed: October 24, 2008
    Publication date: October 29, 2009
    Applicant: REXAHN PHARMACEUTICALS, INC.
    Inventors: Young B. Lee, Deog J. Kim, Chang H. Ahn, Edward C. Scholtz